Biogen raised its annual earnings guidance and exceeded Q3 expectations, with EPS at $4.08 and revenue at $2.47 billion. The company's shares rose by 3% in premarket trading. Biogen's Alzheimer's drug sales increased to $67 million.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing